This is the authors' abstract. We don't add key points for this paper.
ConceptGene therapy with adeno-associated virus (AAV) vectors treats hemophilia A or B by delivering a functional F8 or F9 gene to hepatocytes.This single infusion enables endogenous production of factor VIII (FVIII) or FIX protein, reducing bleeding in patients (Figure ) Evolution Long-term clinical studies have provided insight into the efficacy, safety, and durability of AAV-mediated gene therapies for hemophilia A 1,2 and B. 3-5 Gene therapies have now been approved for hemophilia A (valoctocogene roxaparvovec) and hemophilia B (etranacogene dezaparvovec and fidanacogene elaparvovec) in select regions. ApplicationThe approved gene therapies are associated with a significant reduction in bleeding tendency and increased FVIII or FIX activity levels, without the need for additional FVIII or FIX replacement therapies, in the vast majority of patients.3,6 Future steps Improvements in AAV technology, protein expression, and immunogenicity may make AAV-mediated gene therapies more efficient, longer lasting, and safer for people with hemophilia A or B.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lenting et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: